iShares Russell 2000 ETF vs uniQure N.V. Ordinary Shares — how do they compare? iShares Russell 2000 ETF trades at $272.04 (market cap $77.75B), while uniQure N.V. Ordinary Shares trades at $20.78 (market cap $1.48B). The key difference: iShares Russell 2000 ETF is far larger — about 52.5× uniQure N.V. Ordinary Shares's market cap, and iShares Russell 2000 ETF is trading nearer its 52-week high, uniQure N.V. Ordinary Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares Russell 2000 ETF for 83 Days and uniQure N.V. Ordinary Shares for 0 Days on average.
| IWM | QURE | |
|---|---|---|
Market Cap | $77.75B | $1.48B |
Volume | 27,728,271 | 2,488,780 |
52-Week High | $305.06 | $70.59 |
52-Week Low | $229.13 | $9.03 |
Typical Hold Time | 83 Days | 0 Days |
Sector | — | Health |
Enterprise Value | — | $728.62M |
Signals from Pluang's Aura AI — not financial advice
IWM trades at $276.71, down 0.42% with bearish technical signals from moving averages. The ETF faces headwinds as small-caps underperform large-caps, with recent Fed rate hikes pressuring the sector. Technical indicators show oversold conditions with RSI at 38.61, while support sits at $276. Recent news highlights IWM's decade-long underperformance versus the S&P 500, raising questions about the small-cap premium.
The outlook remains cautious given macroeconomic pressures and sector rotation away from small-caps. Higher interest rates typically disadvantage small companies with greater borrowing needs, while broader market concentration in tech giants reduces small-cap participation. However, current valuations may offer long-term value if economic conditions stabilize.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
The ETF is designed to track the performance of the securities and the stocks in the Russell 2000 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on IWM →uniQure N.V. is a biotechnology company that develops gene therapies for rare and severe genetic diseases, marketing HEMGENIX for hemophilia B and advancing its AAV-based miQURE platform in programs such as AMT-130 for Huntington's disease.
Read more on QURE →